Eidogen-Sertanty Licenses TIP to the FDA
Eidogen-Sertanty licensed their Target Informatics Platform (TIP) to the U.S. Food and Drug Administration's National Center for Toxicological Research (NCTR).
SAN DIEGO, Dec. 8 /PRNewswire/ -- Eidogen-Sertanty, Inc., a San
Diego-based computational drug discovery solutions provider,
announced today they have licensed their Target Informatics
Platform (TIP) to the U.S. Food and Drug Administration's National
Center for Toxicological Research (NCTR).
Under the terms of the license, scientists within NCTR will have
access to the complete TIP structural knowledgebase via onlineTIP
as well as access to the TIP/Workgroup technology for internal
research. Eidogen-Sertanty will also participate in several
NCTR-led projects including the multi-year PADRE project (MAQC-IV),
which is focusing on the modeling of drug-protein interactions to
identify new genetic variations that may lead to serious adverse
drug reactions.
"We're extremely pleased to have licensed the TIP technology to
the FDA/NCTR," said Dr. Steven Muskal, Eidogen-Sertanty's Chief
Executive Officer. "We very much look forward to having a positive
impact in the FDA's effort to predict serious adverse drug
reactions at the individual patient level."
Eidogen-Sertanty contact: Steve Muskal 760-651-2885 pr@eidogen-sertanty.com About Eidogen-Sertanty
Eidogen-Sertanty, formed in March 2005 from the merger of
Eidogen and Sertanty, is a privately held company providing
pioneering knowledge-driven discovery solutions to biotechnology
and pharmaceutical organizations. Eidogen-Sertanty's unique and
powerful suite of software, databases, and drug discovery services
enable customers and collaborators to apply a knowledge-driven
discovery approach to a variety of workflows and processes,
including target selection and prioritization, library building and
compound prioritization, and lead design and optimization. To find
out more about Eidogen-Sertanty and their products and services,
please visit www.eidogen-sertanty.com.
This press release was issued through 24-7PressRelease.com. For
further information, visit http://www.24-7pressrelease.com/.
Source: Eidogen-Sertanty
CONTACT: Steven Muskal of Eidogen-Sertanty,
+1-760-651-2885,
pr@eidogen-sertanty.com
Web Site: http://www.eidogen-sertanty.com/
Posted: December 2009
